SailPoint Levels-Up their ABM Strategy with Intent Data

| July 15, 2019

The buyer’s journey has changed in a way which leaves many sales and marketing teams struggling to find insight from within what we call the Dark Funnel. However, many technology companies are starting to build solutions to address the radical new way customers engage and buy today by collecting and organizing intent data as well as building systems to scale these processes. Phil Tran, Sr. Manager, Marketing Operations at SailPoint, an Austin, Texas-based cybersecurity software company that delivers identity governance to enterprises of all sizes around the world, sat down with me to talk about what led SailPoint to 6sense and how their ABM strategy has improved by uncovering, prioritizing, and engaging with demand to drive more revenue.
Become a contributor

Spotlight

Drug Discovery World

Welcome to our LinkedIn page. This is where we will share articles from our lastest issues, as well as news and other company updates. Now in its 18th year, DDW is the only truly global business review of all aspects of drug discovery and development and has firmly established itself as a highly respected and ‘must read’ journal within the discovery and development arena. DDW is renowned for voicing the opinions of some of the Industry’s leading luminaries and has become a recognised ‘platform’ for ‘Industry Gurus’ to discuss and encourage debate on some of the more challenging issues surrounding the technological, strategic and business facets of the pharma and biopharmaceutical industry. DDW has always adhered to the maxim.’Turning Science into Business’.

Spotlight

Drug Discovery World

Welcome to our LinkedIn page. This is where we will share articles from our lastest issues, as well as news and other company updates. Now in its 18th year, DDW is the only truly global business review of all aspects of drug discovery and development and has firmly established itself as a highly respected and ‘must read’ journal within the discovery and development arena. DDW is renowned for voicing the opinions of some of the Industry’s leading luminaries and has become a recognised ‘platform’ for ‘Industry Gurus’ to discuss and encourage debate on some of the more challenging issues surrounding the technological, strategic and business facets of the pharma and biopharmaceutical industry. DDW has always adhered to the maxim.’Turning Science into Business’.

RELATED ARTICLES